Browsing Category
Pharma Industry News
4730 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Why Immunome’s Phase 3 varegacestat data could reshape the desmoid tumor treatment market
Immunome is set to release Phase 3 varegacestat data that could redefine its oncology strategy and valuation. Read what this catalyst really means.
Eli Lilly’s Inluriyo and Verzenio combo data reshape outlook for ER+, HER2– metastatic breast cancer treatment
Eli Lilly’s EMBER-3 update boosts Inluriyo’s profile in breast cancer care—find out how its all-oral combo with Verzenio could shift treatment standards.
Milestone Pharmaceuticals (NASDAQ: MIST) gets FDA green light for etripamil nasal spray
Discover how Milestone Pharmaceuticals’ FDA approval of CARDAMYST (etripamil) is reshaping PSVT treatment and setting the stage for broader cardiovascular care. Read more.
Vaxxas’ TGA licence unlocks GMP production for HD-MAP vaccines: What this means for clinical trials and global delivery strategy
Vaxxas Pty Ltd wins TGA manufacturing licence for needle‑free HD‑MAP vaccines, enhancing clinical scale and delivery potential. Find out what this means next.
Biocon Biologics (NSE: BIOCON) clears global aflibercept deal with Regeneron, Bayer for Yesafili rollout
Biocon Biologics secures global aflibercept launch rights for Yesafili after Regeneron–Bayer settlement. Find out what this means for biosimilar strategy.
Cynata Therapeutics (ASX: CYP) completes Phase 2 enrolment for CYP-001 as investors refocus on June 2026 data inflection
Cynata Therapeutics completes Phase 2 enrolment for CYP-001, shifting focus to June 2026 data. Read what this means for strategy, risk, and valuation.
Johnson & Johnson expands AKEEGA’s reach with FDA nod in BRCA2-mutated metastatic castration-sensitive prostate cancer
Johnson & Johnson’s AKEEGA secures FDA approval for BRCA2-mutated prostate cancer, reshaping early-stage treatment and signaling a shift toward genomic-first therapy.
Sobi bets on late-stage gout asset with acquisition of Arthrosi Therapeutics
Swedish Orphan Biovitrum is acquiring Arthrosi Therapeutics for $950 million to bolster its inflammation pipeline. Explore what this means for its growth trajectory.
Rezolute shares plunge after Phase 3 sunRIZE study fails to show significant benefit in congenital hyperinsulinism
Rezolute shares collapsed after its Phase 3 sunRIZE trial failed in congenital hyperinsulinism. Find out what went wrong and what it means for investors now.
CVKD expands clinical pipeline with acquisition of VLX-1005, a Phase 2 12-LOX inhibitor for HIT patients
Discover how Cadrenal Therapeutics’ acquisition of VLX-1005 could reshape treatment options for heparin-induced thrombocytopenia and strengthen its anticoagulation pipeline.